Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Interest & Investment Income: 2020-2025

Historic Interest & Investment Income for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $3.3 million.

  • Mirum Pharmaceuticals' Interest & Investment Income fell 6.28% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year decrease of 12.89%. This contributed to the annual value of $13.8 million for FY2024, which is 0.41% up from last year.
  • Mirum Pharmaceuticals' Interest & Investment Income amounted to $3.3 million in Q3 2025, which was up 7.19% from $3.0 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Interest & Investment Income registered a high of $4.1 million during Q3 2023, and its lowest value of $65,000 during Q4 2021.
  • In the last 3 years, Mirum Pharmaceuticals' Interest & Investment Income had a median value of $3.5 million in 2024 and averaged $3.3 million.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Interest & Investment Income slumped by 80.25% in 2021, and later spiked by 3,196.92% in 2022.
  • Mirum Pharmaceuticals' Interest & Investment Income (Quarterly) stood at $65,000 in 2021, then skyrocketed by 3,196.92% to $2.1 million in 2022, then spiked by 76.15% to $3.8 million in 2023, then dropped by 15.13% to $3.2 million in 2024, then dropped by 6.28% to $3.3 million in 2025.
  • Its last three reported values are $3.3 million in Q3 2025, $3.0 million for Q2 2025, and $3.0 million during Q1 2025.